Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A meningioma that occurs during childhood.
Biomarker and diagnostic research for pediatric meningioma has been reported in the published literature.
88 clinical trials registered, 52 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and medical devices. Pipeline includes 2 PHASE4, 2 PHASE3, 23 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07150806](https://clinicaltrials.gov/study/NCT07150806) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma |
PHASE1 |
Joshua Palmer |
RECRUITING |
[NCT06326190](https://clinicaltrials.gov/study/NCT06326190) | 177Lu-DOTATATE for Recurrent Meningioma | PHASE2 | European Organisation for Research and Treatment of Cancer - EORTC | RECRUITING |
[NCT06126588](https://clinicaltrials.gov/study/NCT06126588) | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial | PHASE2 | Central Hospital, Nancy, France | RECRUITING |
[NCT05727605](https://clinicaltrials.gov/study/NCT05727605) | Neurocognition After Radiotherapy in CNS- and Skull-base Tumors | NA | Universitaire Ziekenhuizen KU Leuven | RECRUITING |
[NCT07428616](https://clinicaltrials.gov/study/NCT07428616) | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | PHASE2 | Exelixis | RECRUITING |
163 publications have been identified in PubMed for pediatric meningioma. Research spans Review / Meta-Analysis (33%), Basic Science / Preclinical (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 53 | 33% |
Laboratory research | 27 | 17% |
Disease patterns and progression | 27 | 17% |
Patient case studies | 16 | 10% |
Testing and diagnosis research | 14 | 9% |
Clinical study results | 10 | 6% |
New treatment approaches | 10 | 6% |
Other research | 6 | 4% |
Joseph J (2026). [PMID: 41973674](https://pubmed.ncbi.nlm.nih.gov/41973674/). *Pediatr Neurosurg*. [Epidemiology / Natural History]
Gong X (2026). [PMID: 41664563](https://pubmed.ncbi.nlm.nih.gov/41664563/). *Brain Behav*. [Epidemiology / Natural History]
Guo X (2026). [PMID: 41630100](https://pubmed.ncbi.nlm.nih.gov/41630100/). *Neuro Oncol*. [Basic Science / Preclinical]
Aso T (2026). [PMID: 41589518](https://pubmed.ncbi.nlm.nih.gov/41589518/). *Diagn Cytopathol*. [Case Report / Case Series]
Gujral J (2026). [PMID: 41693498](https://pubmed.ncbi.nlm.nih.gov/41693498/). *Nucl Med Commun*. [Review / Meta-Analysis]
Walpole S (2026). [PMID: 41277477](https://pubmed.ncbi.nlm.nih.gov/41277477/). *Clin Genet*. [Case Report / Case Series]
Yin K (2026). [PMID: 42059606](https://pubmed.ncbi.nlm.nih.gov/42059606/). *Microbiol Spectr*. [Diagnostic / Biomarker]
Ye E (2026). [PMID: 41526775](https://pubmed.ncbi.nlm.nih.gov/41526775/). *Childs Nerv Syst*. [Review / Meta-Analysis]
Juncà A (2026). [PMID: 41521239](https://pubmed.ncbi.nlm.nih.gov/41521239/). *Sci Rep*. [Basic Science / Preclinical]
Visocchi E (2026). [PMID: 42144485](https://pubmed.ncbi.nlm.nih.gov/42144485/). *Childs Nerv Syst*. [Review / Meta-Analysis]
AI-curated news mentioning pediatric meningioma
Updated Jul 14, 2026
A systematic review of WHO grade 3 pediatric meningioma highlights key clinical features and prognostic factors affecting patient outcomes. This analysis provides valuable insights for clinicians managing this rare tumor type.